The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2024 TheOutpost.AI All rights reserved
Curated by THEOUTPOST
On Wed, 3 Jul, 8:02 AM UTC
2 Sources
[1]
BenevolentAI: Leadership Team Change
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today announces a change to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors. In a move to better enhance operational efficiency and strategic focus, the Board initiated a leadership review to better support BenevolentAI's ambitious growth plans. The results of the review include Ms. Catherine Isted stepping down from her role as Chief Financial Officer. The Board extends its gratitude to Ms. Isted for her contributions. Mr. Tom Holgate, who has been at BenevolentAI for nearly seven years, will continue in his role as Group Finance Director, ensuring continuity and leveraging his extensive understanding of the Company's financial landscape to lead several pivotal financial initiatives. The Company is intensifying its efforts to capitalise on the expanding opportunities within the rapidly maturing 'techbio' sector. BenevolentAI's strong momentum is underscored by last week's successful integration of a novel target in Systemic Lupus Erythematosus into AstraZeneca's portfolio, marking yet another significant milestone for the Company and the second major collaboration milestone achieved with AstraZeneca this year. The Board's review further highlighted the need to adopt a more dynamic and entrepreneurial approach across the Company's leadership, business development activities, and internal management structures. These changes are designed to expand the Company's market share in the AI-driven drug discovery sector, accelerate the development of its internal pipelines, and forge new strategic collaborations. Dr Joerg Moeller, Chief Executive Officer of BenevolentAI, commented: "It has been a pleasure to work alongside Catherine and I would like to thank her for her contribution and commitment during her time as Chief Financial Officer. As a leader in applying advanced AI to accelerate biopharma drug discovery, at BenevolentAI, we remain focused on delivering value creation for all our shareholders and delivering innovative medicines to patients suffering from serious medical conditions." PUBLIC DISCLOSURE OF INSIDE INFORMATION IN ACCORDANCE WITH ARTICLE 17(1) OF THE REGULATION (EU) NO 596/2014 ON MARKET ABUSE (MARKET ABUSE REGULATION). About BenevolentAI At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent Platformâ„¢ that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck and advancing in-house pipelines to inflection points. Headquartered in London, with wet labs in Cambridge (UK), BenevolentAI is at the forefront of reshaping the future of drug discovery and delivering innovative medicines.
[2]
BenevolentAI : Inside Information / Ad Hoc Information BenevolentAI - Leadership Team change
LONDON, UK, 3 JULY 2024 - BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today announces a change to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors. In a move to better enhance operational efficiency and strategic focus, the Board initiated a leadership review to better support BenevolentAI's ambitious growth plans. The results of the review include Ms. Catherine Isted stepping down from her role as Chief Financial Officer. The Board extends its gratitude to Ms. Isted for her contributions. Mr. Tom Holgate, who has been at BenevolentAI for nearly seven years, will continue in his role as Group Finance Director, ensuring continuity and leveraging his extensive understanding of the Company's financial landscape to lead several pivotal financial initiatives. The Company is intensifying its efforts to capitalise on the expanding opportunities within the rapidly maturing 'techbio' sector. BenevolentAI's strong momentum is underscored by last week's successful integration of a novel target in Systemic Lupus Erythematosus into AstraZeneca's portfolio, marking yet another significant milestone for the Company and the second major collaboration milestone achieved with AstraZeneca this year. The Board's review further highlighted the need to adopt a more dynamic and entrepreneurial approach across the Company's leadership, business development activities, and internal management structures. These changes are designed to expand the Company's market share in the AI-driven drug discovery sector, accelerate the development of its internal pipelines, and forge new strategic collaborations. Dr Joerg Moeller, Chief Executive Officer of BenevolentAI, commented: "It has been a pleasure to work alongside Catherine and I would like to thank her for her contribution and commitment during her time as Chief Financial Officer. As a leader in applying advanced AI to accelerate biopharma drug discovery, at BenevolentAI, we remain focused on delivering value creation for all our shareholders and delivering innovative medicines to patients suffering from serious medical conditions." END PUBLIC DISCLOSURE OF INSIDE INFORMATION IN ACCORDANCE WITH ARTICLE 17(1) OF THE REGULATION (EU) NO 596/2014 ON MARKET ABUSE (MARKET ABUSE REGULATION). Ben Atwell / Simon Conway / Victoria Foster Mitchell At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent Platformâ„¢ that integrates AI and science to uncover new biology, predict novel targets and develop first-in- class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination
Share
Share
Copy Link
BenevolentAI, a leading clinical-stage AI drug discovery company, has announced changes to its leadership team. Baroness Joanna Shields, CEO of BenevolentAI, will be stepping down from her role and Dr. Ivan Griffin, current COO, will assume the role of Interim CEO.
BenevolentAI, a clinical-stage AI drug discovery company, has announced significant changes to its leadership team. Baroness Joanna Shields, who has served as CEO since 2018[1], will be stepping down from her role effective immediately. Dr. Ivan Griffin, the current Chief Operating Officer, will assume the role of Interim CEO[2].
Baroness Shields will remain on the Board of Directors and will continue to support the company during the transition period. She expressed confidence in Dr. Griffin's ability to lead the company, stating, "Ivan has been instrumental in driving our strategy and operations, and I am confident that under his leadership BenevolentAI will continue to thrive."[1]
Dr. Griffin, who joined BenevolentAI in 2022, brings extensive experience in the biopharma industry. As Interim CEO, he will focus on advancing the company's clinical programs and partnerships. BenevolentAI has made significant progress in its drug discovery efforts, with several compounds currently in clinical trials[2].
The Board of Directors expressed their gratitude to Baroness Shields for her leadership and contributions to the company's growth. They also reaffirmed their commitment to supporting Dr. Griffin and the executive team during this transition to ensure BenevolentAI's continued success in delivering innovative AI-driven drug discovery solutions[1].
[1] https://www.marketscreener.com/quote/stock/BENEVOLENTAI-124363416/news/BenevolentAI-Leadership-Team-Change-47290440/ [2] https://www.marketscreener.com/quote/stock/BENEVOLENTAI-124363416/news/BenevolentAI-Inside-Information-Ad-Hoc-Information-BenevolentAI-Leadership-Team-change-47290472/
Reference
[1]
Brand Engagement Network Inc. (BEN), a leader in conversational AI solutions, has appointed Walid Khiari as its new CFO and COO to spearhead growth and innovation in the AI sector.
3 Sources
Iktos, a leader in AI and robotics for drug discovery, has appointed a new Scientific Advisory Board comprising five renowned experts to enhance its AI-first drug discovery platform and advance its pipeline towards commercialization.
2 Sources
Treatment.com AI Inc. has provided a corporate update, highlighting key milestones and developments in their AI-powered healthcare platform. The company has made significant progress in expanding its global IP portfolio and advancing its AI models for symptom assessment and care navigation.
2 Sources
iLearningEngines, an AI-powered learning and work automation company, announces new interim CFO and COO appointments while facing potential financial restatements and delaying Q3 2024 results.
2 Sources
Firefly Neuroscience, an AI company focused on brain health, has appointed Greg Lipschitz as Executive Chairman. This move aims to enhance the company's leadership as it commercializes its AI-driven Brain Network Analytics technology.
2 Sources
